ARIEL2 Trial: Hopes in Optimizing Predictor of Response

SGO2017 has 36 videos Subscribe Here

Description: Elizabeth Swisher, MD of University of Washington Medical Center discusses her hopes in the ARIEL2 Trial in helping to optimize predictor of response for patients with not only ovarian cancer, but other cancers as well. She states that ovarian cancer is the leading factor in the field of PARP inhibitors and what is learned in ovarian cancer can be applicable to other cancers. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® in National Harbor, MD.
Shared By : SGO2017
Posted on : 03/31/17
Added : 8 months ago
Category : Ovarian Cancer


Nothing found.

More From SGO2017

Nothing found.